Critical appraisal of effects of @entity172 replacement therapy on symptoms of XXXX mood.

@entity172 @entity1 @entity308 @entity2494 @entity1109 @entity53 @entity3010
That @entity172 plays a role in the regulation of mood has been postulated since extracts of animal ovarian tissue were administered to oophorectomized @entity1 at the end of the last century to @entity1109 thought to be related to the removal of the ovaries. The occurrence of @entity308 in the perimenopause is associated with a variety of factors. A previous history of either @entity308 and/or @entity3010 as well as cognitive factors explain most of the variance. There are no consistent findings of a correlation between any serum hormone level and severity or presence of mood symptoms. Neurobiological studies show, with regard to an antidepressant effect, promising effects of @entity53 on serotonergic, noradrenergic, cholinergic, dopaminergic and GABAergic functions. Progestogens seem to oppose some of these effects. The role of adrenergic hormones and @entity2494 (S) is less clear. Most clinical trials showed a modest effect on symptoms of @entity308 . However, the predominantly poor methodological quality does not allow generalisation and recommendations. A "tonic" effect on well-being in non- or mild @entity308 @entity1 should not be regarded as true antidepressant effect. Results yielded in studies of surgically menopausal @entity1 may not be applicable to @entity1 with natural menopause. There is a great potential for exploring various types, doses, and routes of administration of both antidepressants and sex hormones. With regard to the domino theory, future studies should also focus on the mediation of treatment effects through alleviation of vasomotor symptoms or sleep quality.
